Trends in Angiotensin Receptor Blocker Use Among those at Risk for COVID-19 Morbidity and

Mortality in the United States

Alexandra Perez, Pharm.D., M.S. Associate professor Department of Sociobehavioral and Administrative Pharmacy Nova Southeastern University College of Pharmacy 3200 S. University Dr. Davie, FL 33328 Email: <u>alperez@nova.edu</u>

Robert Speth, Ph.D., FAAAS Professor, Department of Pharmaceutical Sciences Nova Southeastern University College of Pharmacy 3200 S. University Dr. Davie, FL 33328 Email: rs1251@nova.edu Adjunct Professor, Department of Pharmacology and Physiology Georgetown University School of Medicine 3900 Reservoir Road, N.W. Washington, D.C. 20057

Juan Saavedra, M.D. Adjunct Professor, Department of Pharmacology and Physiology Georgetown University Medical Center 3900 Reservoir Road, N.W. Bldg. D, Room 287. Washington, D.C. 20057 Telephone 301-910-5505 Email: juan.saavedra@georgetown.edu

Running title: ARB use for COVID-19 comorbidities

Trends in Angiotensin Receptor Blocker Use Among those at Risk for COVID-19 Morbidity and Mortality in the United States

Key Points

Question: What is the prevalence of angiotensin receptor blocker (ARB) use among individuals at higher risk of COVID-19-related complications?

Findings: In a cross-sectional study with data from 39,749 adult participants of the National Health and Nutrition Examination Survey, ARB use ranged between 7.4% and 26.2% among those with one or two respiratory, metabolic, renal and/or cardiovascular diseases. Significant disparities in ARB use were found in participants with preexisting conditions and sociodemographic factors that place them at a higher risk of COVID-19 morbidity and mortality.

Meaning: ARB use is widespread and disproportionate in the United States among people at higher risk of COVID-19 complications.

ABSTRACT

Importance: Assessment of the use of angiotensin receptor blockers (ARBs) in the United States provides insight into prescribing practices, and may inform guidelines, policy measures and research during the COVID-19 pandemic.

Objective: To evaluate trends in ARB use among adults in the United States who have preexisting conditions and sociodemographic risk factors that put them at a higher risk of SARS-CoV-2 infection and COVID-19-related complications and mortality.

Design, setting and participants: This study uses the nationally representative cross-sectional data from the 2005-2018 National Health and Nutrition Examination Survey (NHANES). Participants included 39,749 non-institutionalized U.S. civilian adults who were 20 years and older and those with the most common preexisting conditions and risk factors reported among patients with COVID-19.

Main outcomes and measures: Use of ARBs in the prior 30 days from survey interview.

Results: ARB use ranged from 7.4% [95% CI, 6.5%-8.4%] to 26.2% [95% CI, 19.4%-34.4%] among those with one or two metabolic, renal, respiratory, and/or cardiovascular diseases. Among individuals with the three most common preexisting conditions in patients with COVID-19 including hypertension, diabetes and obesity, ARB use was higher among the elderly, females, non-Hispanic whites, and those with health insurance coverage.

Conclusions and relevance: In this nationally representative survey, ARB use was found to be widespread, but unevenly distributed among individuals with conditions and sociodemographic risk factors that place them at a higher risk of COVID-19 morbidity and mortality.

INTRODUCTION

The COVID-19 pandemic affects not only the lung but multiple organs¹⁻⁷ with high individual variability, in some cases with devastating consequences, leading to chronic disability or death.^{8,9} At the present time, no therapies have been devised to prevent or treat all cases of SARS-CoV-2 infection leading to COVID-19, however, a large number of therapeutic approaches have been proposed and several have been reported to have incremental benefits.¹⁰⁻¹⁴ Thus, it is imperative to identify available compounds that could be repurposed as beneficial, or at the very least palliative, to prevent or ameliorate the severity of the disease.

Some preexisting disorders such as hypertension, cardiovascular and kidney disease, diabetes, and obesity, are frequently comorbid with COVID-19.¹⁵⁻²⁴ These disorders are characterized by enhanced activity of the Renin-Angiotensin System (RAS), in particular, with excessive stimulation of the Angiotensin (Ang) II AT1 receptor (AT1R) type.²⁵ Increased AT1R activity leads to reduced systemic and pulmonary blood flow and oxygen levels, pathological inflammation, fibrosis, reduced sensitivity to insulin, alterations in innate and adaptive immunity, and coagulation defects.²⁶⁻²⁸ This explains why these preexisting conditions significantly increase the risk of poor outcome and death in COVID-19 patients.

It is not surprising that patients afflicted with these illnesses are frequently treated with medications such as Angiotensin Receptor Blockers (ARBs) that antagonize the pathological effects of AT1R hyperactivity.²⁹⁻³² For these reasons, many patients afflicted with COVID-19 comorbidities and infected by SARS-CoV-2 have been previously treated with ARBs at the time of their diagnoses.

Although the use of ARBs for the treatment of hypertension, cardiovascular and metabolic disorders is widespread, data describing the precise prevalence of these medications in risk groups with comorbidities of COVID-19 is lacking. Such data are essential to address the question of the expected number of individuals treated with ARBs in the general population as well as at the time of SARS-CoV-2-infection. The objective of this study is to estimate ARB trends in use among adults in the United States who have preexisting conditions and sociodemographic risk factors that put them at a higher risk of SARS-CoV-2 infection and COVID-19-related complications and mortality. These data will be useful to determine, in future population studies, whether ARB use influences SARS-CoV-2 infection rates, the development of symptoms, the severity of the illness, the prognosis of COVID-19, and the process of recovery.

METHODS

Data Source and Study Population:

The National Health and Nutrition Examination Survey (NHANES) is a nationally representative crosssectional survey of the non-institutionalized civilian population in the United States.³³ This survey consists of questionnaire, physical examination and laboratory components that includes self-reported data of medical history, prescription medication use, and body measures among others. This study used publicly available, deidentified data and did not require institutional review board approval (45 CFR §46.102(f)).

We used data from adults 20 years of age or older and evaluated ARB use within the most prevalent (5% or higher) preexisting conditions reported in the COVID-19 population.³⁴ For this study, data were used from the 7 most recent NHANES biannual cycles being 2005 through 2018.

Assessment of Angiotensin Receptor Blocker Use

The prescription medications survey provides personal interview data on the use of prescription medications during a 30-day period prior to the participant's interview date. All prescription drugs are entered upon interview by generic name. ARB use was defined as use of any angiotensin receptor blocker (losartan, candesartan, olmesartan, azilsartan, eprosartan, irbesartan, telmisartan, and valsartan) either as a single agent or in combination with other drugs.

Statistical Analysis

This study assessed the prevalence of ARBs in the general adult population and within populations of hypertension, diabetes, coronary heart disease, stroke, kidney disease, congestive heart failure, obesity, asthma, and chronic obstructive pulmonary disease (COPD) as shown in Table 1. ARB use was also explored within select populations with 2 concomitant metabolic, renal and cardiovascular diseases and data are presented in eTable 1 in the Supplement. ARB use within NHANES biannual cycle was also assessed in the general adult population and within the previously specified conditions from 2005-2018 (Figure 1 and eTable 2 in the Supplement). Furthermore, the association of ARB use and commonly reported sociodemographic risk factors in those diagnosed with COVID-19 including age, gender, race/ethnicity, household income and educational levels, health and prescription insurance coverage and body mass index were explored within populations with hypertension, diabetes and obesity (defined as $\geq 30 \text{ kg/m}^2$) and are shown in Tables 2-4. These conditions are the three most prevalent comorbidities (30% or higher) among those with COVID-19.³⁴ Similar analyses were conducted within populations with

coronary heart disease, stroke, kidney disease and congestive heart failure and are presented in eTable 3 and eTable 4 in the Supplement. Sociodemographic risk factor heterogeneity was assessed by stratification of age (\leq 44, 45-64 and \geq 65 years), sex (male/female), race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, and other race), income (\geq \$20,000, <\$20,000), education (high school or lower, some college or higher), health insurance coverage (yes/no), prescription insurance coverage (yes/no) and body mass index (\leq 24.99 kg/m², 25-29.99 kg/m², 30-39.99 kg/m², and \geq 40 kg/m²). Prevalent ARB use was calculated within unique risk factor subgroups (e.g., within participants age \leq 44) and distribution across subgroups (e.g., across all age categories). Survey-weighted binomial logistic regression evaluated the association of ARB use, as the dependent variable, and biannual cycle, sociodemographic risk factors and body mass index categories were independent parameters. ARB use prevalence estimates were adjusted for oversampling of older adults, low-income individuals, and racial/ethnic minorities for their unequal sampling probability and nonresponse. Statistical significance was assessed at the 2-sided α =0.05 level. All analyses were conducted using IBM SPSS version 26.0.

RESULTS

Data from 39,749 participant adults aged 20 years and older were used in this study and the sample size for each biannual NHANES cycle ranged from 4979 to 6218. Sample size for populations with hypertension, diabetes and obesity are presented in Tables 2-4. Response rates in NHANES cycles ranged between 71% and 94.3%.³⁵ Table 1 shows the national count and percent of US adults reporting use of an ARB in the general adult population and within populations with select metabolic, respiratory, renal and cardiovascular diseases. 6.4% percent (or 14.4 million people) in the general adult population, regardless of comorbidities, in the US were estimated to be taking ARBs. In the single condition population analysis in Table 1, ARB use was at its lowest among those with asthma (7.4% [95% CI, 6.5%-8.4%, 2.4 million people]) and at its highest among those with diabetes (19.3% [95% CI, 17.8%-20.9%, 4.1 million people]). ARB use was more prevalent within populations with 2 co-existing chronic conditions. As shown in eTable 1 in the Supplement, ARB use prevalence was at its lowest in those with co-existing kidney disease and congestive heart failure (18.7% [95% CI, 12.8%-26.5%, 175,000 people] and at its highest among those theart disease and kidney disease (26.2% [95% CI, 19.4%-34.4%, 197,000 people]).

Figure 1 reports a significant increase in the prevalence of ARB use from 2005 to 2018 in the general adult population (4.5% [95% CI, 3.6%-5.6%] in 2005-2006 and 7.6% [95% CI, 6.5%-8.8%] in 2017-2018, p for trend=0.007). The same trend was observed among those with hypertension (14.5% [95% CI, 11.7%-17.7%] in 2005-2006 and 21.8% [95% CI, 19.0%-24.9%] in 2017-2018, p for trend =0.005), and diabetes (11.3% [95% CI, 8.0%-15.7%] in 2005-2006 and 20.0% [95% CI, 16.7%-23.7%] in 2017-2018,

p for trend =0.02) but not in those with obesity (7.2% [95% CI, 5.4%-9.6%] in 2005-2006 and 9.6% [95% CI, 8.1%-11.2%] in 2017-2018, p for trend =0.12). ARB use among participants with coronary heart disease, stroke, kidney disease, and congestive heart failure did not change across biannual cycles and data are shown in eTable 2 in the Supplement.

Tables 2-4 show the prevalence of ARB use by select sociodemographic risk factors and body mass index categories among those with hypertension, diabetes, and obesity. In these three populations, there was a significant association between ARB use and age groups (p<0.001 for all), gender (p<0.03 for all), race/ethnicity (p<0.001 for all), and health insurance coverage (p<0.001 for all). In those with hypertension and diabetes, a significant association of ARB use and household income (p<0.01 for both), educational level (p<0.04 for both) and body mass index category (p<0.0001 for both) was observed. Odds ratios in Tables 2-4 indicate that ARB use in those with hypertension, diabetes and obesity increased with age, was higher among females than males, non-Hispanic whites compared to minorities and in those with health insurance coverage. In those with hypertension and diabetes, ARB use was higher among the evel evel. Prescription insurance coverage was not associated with ARB use in any of the populations evaluated. eTables 3 and eTable 4 in the Supplement show the prevalence of ARB use among participants with coronary heart disease, stroke, kidney disease, and congestive heart failure and show similar trends in ARB use within sociodemographic risk factors.

DISCUSSION

Our results demonstrate that ARB use is prevalent for conditions that increase the risk of SARS-CoV-2 infection and increase COVID-19 morbidity and mortality. ARB use in the United States in the general adult population is 6.4% and ranging between 7.4% and 26.2% among those with one or two metabolic, respiratory, renal and cardiovascular diseases prevalent in the COVID-19 population. Over time, ARB use has increased in the general population and among those with hypertension and diabetes but not in the other conditions evaluated. Overall, ARB use was most prevalent with increasing age, among females, non-Hispanic whites, those with health insurance coverage, and higher income, educational level and body mass index categories in many of the populations evaluated including hypertension, diabetes, obesity and other cardiovascular diseases.

Along with other antihypertensive agents, ARBs are currently indicated to be initial treatment for hypertension among non-Blacks and as secondary treatment for Blacks.³⁶ However, ARBs or ACE inhibitors are recommended for treatment of hypertension in all patients with diabetes.³⁶ ARBs are very well tolerated, including in the elderly, increasingly available in the therapeutic arsenal as generic drugs,

and with significant beneficial properties beyond their effect on blood pressure, such as potently reducing inflammation and fibrosis and mitigating the adverse effects of metabolic syndrome.³⁷⁻⁴¹ As a consequence, there is increasing interest to consider ARB treatment for a larger number of disorders beyond hypertension. There are 1,724 clinical studies presently testing the use of ARBs not only for cardiovascular disease, but for many other clinical conditions.⁴² For these reasons it is expected that a large and increasing number of patients will be medicated with ARBs at the time of their COVID-19 diagnosis.

Initial concerns for continued use of ARBs in COVID-19 patients have been rebutted, with the consensus now being that ARBs should not be withdrawn when prescribed for comorbidities, since they do not adversely influence COVID-19 prognosis and progression.^{37,40,43-47} Moreover, it is possible that treatment with ARBs might actually be beneficial, since these compounds protect lung function, reducing pneumonia-related deaths associated with hyper-inflammation.⁴⁸⁻⁵² Preliminary reports now suggest that ARBs may reduce COVID-19 disease severity.⁵³⁻⁵⁵ A large-scale observational study of hospitalized COVID-19 patients with preexisting hypertension demonstrated a profound reduction in mortality in patients taking ARBs compared to other antihypertensive drugs.⁵⁵

Nevertheless, it is most important to clearly determine whether ARBs could be beneficial to ameliorate or delay COVID-19 progress, reduce mortality and improve health during recovery, and the effects of ARBs on COVID-19 patients are under intense scrutiny. To this date (07/17/2020), there are 45 ongoing prospective clinical trials registered with clinicaltrials.gov ⁴² to determine the precise impact of ARB use in COVID-19 patients.

Our data also demonstrate that while ARBs are frequently prescribed for patients with COVID-19 comorbidities, ARB use is not uniform within the US population. The incidence of COVID-19 is higher among individuals with lower socioeconomic status who are subject to increased exposure to SARS-CoV-2 by virtue of their need to continue working in environments prone to contagion, as well as living in a crowded home environment. COVID-19 incidence is also higher in elderly, males, racial/ethnic minority (i.e., Hispanics, Blacks and Native Americans) populations, as well as those patients previously affected by hypertension, diabetes, obesity, cardiovascular and kidney disease; considered to be risk factors and co-morbidities.¹⁵⁻²⁴ In this study, we found ARB use to be lowest in these sociodemographic subgroups.

For these reasons, determination of ARB benefit should be tempered by the consideration that those individuals treated with ARBs may have better overall physical health and less intense exposure to the coronavirus, confounding factors to consider when reaching final conclusions on ARB benefits.

Comparison of incidence and outcomes of COVID-19 for ARB use compared with other RAS inhibitors such as ACE inhibitors, and other classes of antihypertensive drugs are under way.⁴²

Our study has several limitations: 1) since survey participants were non-institutionalized civilians, the study results may not be extrapolated to those living in nursing homes or incarcerated individuals where COVID-19 has been prevalent and should only be generalized to the community-dwelling US adult population; 2) diagnoses of the comorbidities and medication use presented here are based on self-report and may be subject to error due to recall bias; and 3) this study does not address the use of single ARB therapy compared with the use of ARBs combined with additional antihypertensive drugs or compliance to treatment. Evaluation of the use of ARBs among the highly affected Native American population was not possible in this study.

In conclusion, our report will inform both clinical practice and research, and will be useful in prioritizing future studies on whether ARB use influences SARS-CoV-2 infection rates, the development of symptoms, the severity of the illness, the prognosis of COVID-19, and the process of recovery in the subpopulations evaluated here.

References

- 1. Aguila EJT, Cua IHY, Fontanilla JAC, Yabut VLM, Causing MFP. Gastrointestinal Manifestations of COVID-19: Impact on Nutrition Practices. *Nutr Clin Pract.* 2020.
- 2. Hardenberg JH, Luft FC. Covid-19, ACE2, and the kidney. *Acta Physiol (Oxf)*. 2020:e13539.
- 3. Kukla M, Skonieczna-Zydecka K, Kotfis K, et al. COVID-19, MERS and SARS with Concomitant Liver Injury-Systematic Review of the Existing Literature. *J Clin Med.* 2020;9(5).
- 4. Nakra NA, Blumberg DA, Herrera-Guerra A, Lakshminrusimha S. Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management. *Children (Basel)*. 2020;7(7).
- 5. Speth MM, Singer-Cornelius T, Oberle M, Gengler I, Brockmeier SJ, Sedaghat AR. Mood, anxiety and olfactory dysfunction in COVID-19: evidence of central nervous system involvement? *Laryngoscope*. 2020.
- 6. Wu L, O'Kane AM, Peng H, Bi Y, Motriuk-Smith D, Ren J. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management. *Biochem Pharmacol.* 2020;178:114114.
- 7. Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. *Brain Behav Immun.* 2020;87:18-22.
- 8. Fang X, Li S, Yu H, et al. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. *Aging (Albany NY)*. 2020;12.
- 9. Gupta S, Hayek SS, Wang W, et al. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. *JAMA Intern Med.* 2020.
- 10. Abdolahi N, Kaheh E, Golsha R, et al. Letter to the editor: efficacy of different methods of combination regimen administrations including dexamethasone, intravenous immunoglobulin, and interferon-beta to treat critically ill COVID-19 patients: a structured summary of a study protocol for a randomized controlled trial. *Trials*. 2020;21(1):549.

- 11. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 -Preliminary Report. *The New England journal of medicine*. 2020.
- 12. Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. *JAMA*. 2020.
- 13. Sohag AAM, Hannan MA, Rahman S, et al. Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review. *Drug Dev Res.* 2020.
- 14. Group RC, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 Preliminary Report. *The New England journal of medicine*. 2020.
- 15. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) United States, February 12-March 16, 2020. *MMWR Morbidity and mortality weekly report*. 2020;69(12):343-346.
- 16. Bolourian A, Mojtahedi Z. Obesity and COVID-19: The mTOR pathway as a possible culprit. *Obesity reviews : an official journal of the International Association for the Study of Obesity.* 2020.
- 17. Esai Selvan M. Publisher Correction: Risk factors for death from COVID-19. *Nat Rev Immunol.* 2020;20(7):448.
- 18. Espinosa OA, Zanetti ADS, Antunes EF, Longhi FG, Matos TA, Battaglini PF. Prevalence of comorbidities in patients and mortality cases affected by SARS-CoV2: a systematic review and meta-analysis. *Rev Inst Med Trop Sao Paulo*. 2020;62:e43.
- 19. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. *MMWR Morbidity and mortality weekly report*. 2020;69(15):458-464.
- 20. Kassir R. Risk of COVID-19 for patients with obesity. *Obesity reviews : an official journal of the International Association for the Study of Obesity*. 2020;21(6):e13034.
- 21. Klang E, Kassim G, Soffer S, Freeman R, Levin MA, Reich DL. Morbid Obesity as an Independent Risk Factor for COVID-19 Mortality in Hospitalized Patients Younger than 50. *Obesity (Silver Spring, Md).* 2020.
- 22. Preskorn SH. The 5% of the Population at High Risk for Severe COVID-19 Infection Is Identifiable and Needs to Be Taken Into Account When Reopening the Economy. *J Psychiatr Pract.* 2020;26(3):219-227.
- 23. Singh AK, Gillies CL, Singh R, et al. Prevalence of comorbidities and their association with mortality in patients with COVID-19: A Systematic Review and Meta-analysis. *Diabetes, obesity & metabolism.* 2020.
- 24. Xu L, Mao Y, Chen G. Risk factors for 2019 novel coronavirus disease (COVID-19) patients progressing to critical illness: a systematic review and meta-analysis. *Aging (Albany NY)*. 2020;12.
- 25. Sfera A, Osorio C, Jafri N, Diaz EL, Campo Maldonado JE. Intoxication With Endogenous Angiotensin II: A COVID-19 Hypothesis. *Front Immunol.* 2020;11:1472.
- 26. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. *Physiol Rev.* 2006;86(3):747-803.
- 27. Rein J, Bader M. Renin-Angiotensin System in Diabetes. *Protein Pept Lett.* 2017;24(9):833-840.
- 28. Takimoto-Ohnishi E, Murakami K. Renin-angiotensin system research: from molecules to the whole body. *J Physiol Sci.* 2019;69(4):581-587.
- 29. Black HR, Bailey J, Zappe D, Samuel R. Valsartan: more than a decade of experience. *Drugs*. 2009;69(17):2393-2414.
- 30. Bochar OM, Sklyarova HY, Faynyk AF, Bochar VT, Kuzminov YB, Bazylevych AY. The effect of therapy with olmesartan or telmisartan in patients with arterial hypertension combined with obesity. *Wiad Lek*. 2020;73(2):321-324.
- 31. Chrysant SG. Clinical experience with the use of angiotensin receptor blockers in patients with cardiovascular, cerebrovascular and renal diseases. *Curr Clin Pharmacol.* 2006;1(2):139-146.

- 32. Schindler C, Bramlage P, Thoenes M, Bramlage C, Kirch W. Cardiovascular risk in obese hypertensive patients taking various antihypertensive drugs. *Clin Drug Investig.* 2007;27(10):707-717.
- 33. NHANES. In: (NCHS) NCfHS, ed. (CDC) CfDCaP, trans. *National Health and Nutrition Examination Survey Data*. Hyattville, MD: US. Department of Health and Human Services, Centers for Disease Control and Prevention.
- 34. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA*. 2020.
- 35. NHANES Response Rates and Population Totals. https://wwwn.cdc.gov/nchs/nhanes/ResponseRates.aspx. Accessed 07/20/2020.
- 36. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014;311(5):507-520.
- 37. Saavedra JM. Angiotensin receptor blockers and COVID-19. *Pharmacol Res.* 2020a;156:104832.
- 38. Sherling DH, Perumareddi P, Hennekens CH. Metabolic Syndrome. *J Cardiovasc Pharmacol Ther.* 2017;22(4):365-367.
- 39. Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. *Int J Obes Relat Metab Disord*. 2004;28(11):1357-1364.
- 40. Speth RC. Keep taking your ACE inhibitors and ARBs during the COVID 19 pandemic. *J Travel Med.* 2020a;27(3).
- 41. Villapol S. Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation. *Cell Mol Neurobiol.* 2018;38(1):121-132.
- 42. ClinicalTrials.gov. clinicaltrial.gov. Accessed 07/17/2020.
- 43. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. <u>https://www.escardio.org/Councils/Council-on-Hypertension-</u> (CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang. Accessed 07/09/2020.
- 44. Bozkurt B, Kovacs R, Harrington B. Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. *J Card Fail.* 2020;26(5):370.
- 45. Saavedra JM. Angiotensin receptor blockers for the treatment of COVID-19 and its comorbidities. *Pharmacol Res.* 2020b;159:104958.
- 46. Saavedra JM. COVID-19, Angiotensin Receptor Blockers, and the Brain. *Cell Mol Neurobiol*. 2020c;40(5):667-674.
- 47. Speth RC. Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections. *Drug Dev Res.* 2020b.
- 48. Fedson DS. Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. *Ann Transl Med.* 2016;4(21):421.
- 49. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. *Drug Dev Res.* 2020.
- 50. Jia H. Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease. *Shock.* 2016;46(3):239-248.
- 51. Schmieder RE. Mechanisms for the clinical benefits of angiotensin II receptor blockers. *American journal of hypertension*. 2005;18(5 Pt 1):720-730.
- 52. Soto M, Bang SI, McCombs J, Rodgers KE. Renin Angiotensin system-modifying therapies are associated with improved pulmonary health. *Clin Diabetes Endocrinol.* 2017;3:6.
- 53. Carey RM, Wang JG. Evidence That Renin-Angiotensin System Inhibitors Should Not Be Discontinued Due to the COVID-19 Pandemic. *Hypertension*. 2020;76(1):42-43.
- 54. Liu Y, Huang F, Xu J, et al. Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. 2020:2020.2003.2020.20039586.

55. Zhou F, Liu YM, Xie J, et al. Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality. *Hypertension*. 2020;76(2):e15-e17.

Diagnoses ^b	All Participants	All Participants	ARB Use	ARB Use
_	No.	9⁄0 ^c	No.	0⁄0 °
	(millions) ^c	(95% CI)	(millions) ^c	(95% CI)
General Adult Population	39749	100	2989	6.4
	(224.376)		(14.359)	(6.0, 6.8)
Hypertension	14227	31.6	2763	19.0
	(70.887)	(30.7, 32.6)	(13.477)	(17.9, 20.2)
Diabetes	5137	9.7	1034	19.3
	(21.357)	(9.3, 10.2)	(4.121)	(17.8, 20.9)
Coronary Heart Disease	1644	3.5	331	18.5
	(7.740)	(3.2, 3.8)	(1.431)	(15.8, 21.5)
Stroke	1591	2.9	281	17.2
	(6.583)	(2.7, 3.2)	(1.134)	(14.9, 19.9)
Kidney Disease	1322	2.6	244	16.8
	(5.784)	(2.4, 2.8)	(0.969)	(13.8, 20.3)
Congestive Heart Failure	1355	2.4 (2.2, 2.6)	258	18.3
	(5.458)		(1.001)	(15.8, 21.2)
Obesity	14296	37.2	1528	9.5
	(79.530)	(36.2, 38.2)	(7.554)	(8.8, 10.2)
Asthma	5637	14.7	526	7.4
	(32.932)	(14.1, 15.3)	(2.423)	(6.5, 8.4)
Chronic Obstructive	679	3.7	100	12.6
Pulmonary Disease ^d	(3.680)	(3.1, 4.3)	(0.463)	(9.5, 16.6)

Table 1 Prevalence of ARB use Among US Adults Overall and Those with Select Conditions^a

^a All participants were aged 20 years or older in data of 7 biannual cycles (2005-2018)

^b Diagnoses were obtained from the health questionnaire data via participant self-report

^c Values of millions, %, and 95% CI are weighted to be nationally representative

^d Biannual cycles 2013-2014 thru 2017-2018 only





Figure 1 cont'd Number of Adult Participants .	Across NHANES Biannual	Cycles 2005-2018	Overall and by I	Diabetes, Hyperter	ision and
Obesity Diagnoses					

	2005-2006	2007-2008	2009-2010	2011-2012	2013-2014	2015-2016	2017-2018
Diabetes	4979	5935	6218	5560	5769	5719	5569
Hypertension	1574	2124	2192	2003	2145	2070	2119
Adults	509	757	725	704	722	844	876
Obesity	1647	2049	2285	1873	2083	2188	2171

All trends statistically significant except of angiotensin receptor blocker use among those with obesity (p for trend= 0.12). All data are weighted to be nationally representative. Errors bars indicate 95% CIs.

Total Population (N=14,227, 70.887 million) ^b ARB Use (N=2763, 13.476 million) Prevalence of ARB Use Within Subgroup Prevalence of ARB Use Across Subgroup					Hypertension							
(N=14,227, 70.887 million) ^b (N=2763, 13.476 million) Prevalence of ARB Use Prevalence of ARB Use Within Subgroup Across Subgroup			Total P	opulation			ARB Use					
Parameter Prevalence of ARB Use Prevalence of ARB Use Prevalence of ARB Use Across Subgroup Across Subgroup			(N=14,227, 7	0.887 million) ^b		(N=2	2763, 13.476 millio	on)				
Parameter Within Subgroup Across Subgroup					Р	revalence of ARB	Prevalence of ARB Use					
	Parameter		NY A/h		N	Within Subgroup			ogroup			
100 , 70° NO. 70° OK 70° p-value (millione) ^b (05% CD (05% CD (05% CD))			NO. (millions) ^b	(05% CD)	NO.	% [°]	(05% CI)	%0 °	p-values ^c			
			(111110113)	()3/0(CI)	(111110113)	()370(1)	()3/0 CI)	()3/0(1)	<0.001			
Age <44 $(23/1)$ 20.2 $1/5$ $/.8$ 1.00° 8.5 <0.00	Age	<44	23/1	20.2	1/5	/.8	1.004	8.3	<0.001			
- (14.33) (19.1, 21.4) (1.114) (6.5, 9.3) (6.9, 9.9)	8		(14.333)	(19.1, 21.4)	(1.114)	(6.5, 9.3)	a (0	(6.9, 9.9)	-			
45-64 5/24 44.2 1048 18.5 2.68 42.9		45-64	5724	44.2	1048	18.5	2.68	42.9				
(31.345) (43.1, 45.3) (5.786) (17.0, 20.0) (2.20, 3.28) (40.1, 45.8)			(31.345)	(43.1, 45.3)	(5.786)	(17.0, 20.0)	(2.20, 3.28)	(40.1, 45.8)	-			
>65 6132 35.6 1540 26.1 4.19 48.8		>65	6132	35.6	1540	26.1	4.19	48.8				
<u>(25.210)</u> (34.3, 36.9) (6.576) (24.3, 28.0) (3.41, 5.14) (45.8, 51.8)		=00	(25.210)	(34.3, 36.9)	(6.576)	(24.3, 28.0)	(3.41, 5.14)	(45.8, 51.8)				
Gender Male 6819 47.7 1159 16.2 1.0 40.6 <0.00	Gender	Male	6819	47.7	1159	16.2	1.0	40.6	< 0.001			
(33.814) (46.7, 48.7) (5.470) (15.0, 17.4) (38.2, 43.0)		Iviaic	(33.814)	(46.7, 48.7)	(5.470)	(15.0, 17.4)		(38.2, 43.0)				
Famila 7408 52.3 1604 21.6 1.43 59.4		Famala	7408	52.3	1604	21.6	1.43	59.4				
(37.073) (51.3, 53.3) (8.006) (20.1, 23.2) (1.30, 1.59) (57.0, 61.8)		Female	(37.073)	(51.3, 53.3)	(8.006)	(20.1, 23.2)	(1.30, 1.59)	(57.0, 61.8)				
Base/ Non Hispania white 6139 69.1 1173 19.6 1.0 71.3 0.001	Page/	Non Hignoria white	6139	69.1	1173	19.6	1.0	71.3	0.001			
Kace/ Non-Frispanic white (48.955) $(66.3, 71.7)$ (9.612) $(18.2, 21.2)$ $(67.9, 74.5)$	Kace/	Non-Hispanic white	(48.955)	(66.3, 71.7)	(9.612)	(18.2, 21.2)		(67.9, 74.5)				
Ethnicity 2906 9.9 507 14.7 0.71 7.7	Ethnicity	TT: ·	2906	9.9	507	14.7	0.71	7.7				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	-	Hispanic	(7.001)	(8.5, 11.5)	(1.032)	(13.1, 16.5)	(0.60, 0.83)	(6.1, 9.6)				
3913 14.4 774 18.9 0.95 14.3		NT TT' ' 11 1	3913	14.4	774	18.9	0.95	14.3				
Non-Hispanic black (10.188) $(12.6, 16.3)$ (1.922) $(17.4, 20.5)$ $(0.83, 1.09)$ $(12.1, 16.7)$		Non-Hispanic black	(10.188)	(12.6, 16.3)	(1.922)	(17.4, 20.5)	(0.83, 1.09)	(12.1, 16.7)				
1269 6.7 309 19.2 0.97 6.8			1269	6.7	309	19.2	0.97	6.8				
Other race (4.743) $(5.9, 7.6)$ (0.910) $(16.6, 22.0)$ $(0.80, 1.18)$ $(5.7, 8.0)$		Other race	(4.743)	(5.9, 7.6)	(0.910)	(16.6, 22.0)	(0.80, 1.18)	(5.7, 8.0)				
9842 82.2 2005 19.8 1.39 85.9 <0.00			9842	82.2	2005	19.8	1.39	85.9	< 0.001			
Household Income $\geq 20k$ (55.763) (80.9, 83.5) (11.058) (18.5, 21.2) (1.20, 1.61) (83.9, 87.6)	Household Income	≥\$20k	(55.763)	(80.9, 83.5)	(11.058)	(18.5, 21.2)	(1.20, 1.61)	(83.9, 87.6)				
			3580	17.8	597	15.1	1.0	14.1				
< 20k (12.047) (16.5, 19.1) (1.822) (13.6, 16.8) (12.4, 16.1)		<\$20k	(12.047)	(16.5, 19.1)	(1.822)	(13.6, 16.8)	-	(12.4, 16.1)				
6702 55.9 1386 20.2 1.19 59.4 0.004			6702	55.9	1386	20.2	1.19	59.4	0.004			
Education Some college or higher (39.553) (54.1, 57.6) (7.999) (18.8, 21.8) (1.06, 1.34) (56.3, 62.3)	Education	Some college or higher	(39.553)	(54.1, 57.6)	(7.999)	(18.8, 21.8)	(1.06, 1.34)	(56.3, 62.3)				
7495 44.1 1373 17.5 1.0 40.6			7495	44.1	1373	17.5	1.0	40.6				
High School or lower $(31,234)$ $(42,4,45,9)$ $(5,471)$ $(16,2,18,9)$ $(37,7,43,7)$		High School or lower	(31.234)	(42.4, 45.9	(5.471)	(16.2, 18.9)		(37.7, 43.7)				
Health Insurance Coverage 12386 89.1 2595 20.3 2.71 95.1 <0.00	Health Insurance Coverage		12386	89.1	2595	20.3	2.71	95.1	< 0.001			
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		Yes	(63.052)	(88.0, 90.1)	(12.797)	(19.1. 21.6)	(2.12, 3.47)	(93.8.96.1)	0.001			
$\begin{array}{cccc} (1000) & (1$			1819	10.9	165	86	1.0	49				
No (7716) (99120) (0.662) (70105) (39.62)		No	(7.716)	(99 120)	(0.662)	(7, 0, 10, 5)	1.0	(39.62)				
Prescription 11394 94.4 2411 20.6 1.22 93.5 0.08	Prescription		11394	94.4	2411	20.6	1 22	93.5	0.08			
Insurance Coverage ^f Yes $(13)^{11}$ $(2111)^{11}$ $(2010)^{11}$ $(122)^{11}$ $(500)^{11}$ Insurance Coverage ^f (58.861) (93.2.95.4) (12.104) (19.3.21.9) (0.98.1.51) (92.7.94.1)	Insurance Coverage ^f	Yes	(58.861)	(93 2 95 4)	$(12\ 104)$	(193 219)	(0.98, 1.51)	(927941)	0.00			
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	insurance coverage		968	56	188	17.6	10	65	1			
No (4.111) $(4.6, 6.8)$ (0.722) $(14.8, 20.7)$ $(5.9, 7.3)$		No	(4.111)	(4.6.6.8)	(0.722)	(14.8, 20.7)	1.0	(5.9, 7.3)				

Table 2. Prevalence of Angiotensin Receptor Blocker Use in the Prior 30 days Among US Adults with Hypertension by Sociodemographic Characteristics and Body Mass Index^a

Body Mass Index	$< 24.00 \text{lm}^2$	2453	17.2	363	13.8	1.0	12.5	< 0.001
	≥24.99 kg/m²	(11.552)	(16.3, 18.0)	(1.596)	(11.9, 16.0)		(10.9, 14.3)	
	25.00-29.99 kg/m ²	4254	31.7	816	18.5	1.42	31.0	
		(21.373)	(30.7, 32.8)	(3.965)	(16.7, 20.6)	(1.16, 1.73)	(28.3, 34.0)	
	20.00.20.00.1/2	5205	39.7	1108	20.8	1.64	43.6	
	30.00-39.99 kg/m ²	(26.675)	(38.6, 40.9)	(5.573)	(19.1, 22.6)	(1.37, 1.96)	(40.8, 46.5)	
	> 40,001, / 2	1479	11.4	332	21.4	1.70	12.8	
	≥40.00 kg/m²	(7.657)	(10.6, 12.2)	(1.641)	(18.5, 24.7)	(1.35, 2.15)	(11.0, 14.9)	

Abbreviations: OR; Odds ratio

^a Diagnosis was obtained from the health questionnaire data via participant self-report in data of 7 biannual cycles (2005-2018)

^b Values of millions and percent (95% CI) are weighted to be nationally representative

^c Indicates the odds of being on an angiotensin receptor blocker compared to the reference category

^d Indicates reference category

^eSignificance for the association of angiotensin receptor blocker use and the parameter

^fSurvey question answered by those saying "yes" to having health insurance coverage

		Diabetes						
		Total P	opulation		ARB Use (N=1034, 4.120 r	nillion)	
		(N=5,137, 2	1.357 million)	Pr	evalence of ARB	Use	Prevalence of	ARB Use
			1	Within Subgroup			Across Subgroup	
		No.	0% ^D	No.	% ^b	OR ^c	% ^B	p-value ^e
Parameter		(millions) [®]	(95% CI)	(millions) [®]	(95% CI)	(95% CI)	(95% CI)	
		545	13.5	37	7.5	1.0 ^d	5.2	< 0.001
Age	<=44	(2.877)	(12.3, 14.7)	(0.214)	(4.9, 11.2)		(3.4, 7.9)	
		2201	45.9	390	16.7	2.50	39.8	
	45-64	(9.803)	(44.1, 47.8)	(1.641)	(14.6, 19.1)	(1.54, 4.05)	(35.6, 44.2)	
		2391	40.6	607	26.1	4.38	55.0	
	>=65	(8.677)	(38.7, 42.6)	(2.265)	(23.5, 28.9)	(2.69, 7.13)	(50.6, 59.2)	
G 1	261	2622	50.4	477	17.5	1.0	45.6	0.03
Gender	Male	(10.755)	(48.2, 52.5)	(1.880)	(15.4, 19.8)		(41.3, 50.1)	
	F 1	2515	49.6	557	21.1	1.26	54.4	
	Female	(10.602)	(47.5, 51.8)	(2.240)	(19.0, 23.4)	(1.02, 1.56)	(49.9, 58.7)	
D (N H. 11	1758	60.6	334	19.3	1.0	60.7	< 0.001
Race/	Non-Hispanic white	(12.948)	(57.3, 63.8)	(2.502)	(17.1, 21.8)		(55.6, 65.6)	
Ethnicity		1428	14.8	229	14.2	0.69	10.9	
5	Hispanic	(3.163)	(12.6, 17.3)	(0.448)	(12.5, 16.0)	(0.56, 0.85)	(8.6, 13.8)	
	N 11 ¹ 11 1	1411	15.7	325	22.1	1.19	18.1	
	Non-mispanic black	(3.362)	(13.7, 18.0)	(0.744)	(19.6, 24.9)	(0.96, 1.46)	(14.9, 21.7)	
	0.1	540	8.8	146	22.6	1.22	10.3	
	Other race	(1.884)	(7.6, 10.2)	(0.425)	(19.1, 26.5)	(0.92, 1.62)	(8.4, 12.7)	
II	> \$201-	3422	79.7	717	20.0	1.31	83.0	0.01
Household Income	≥\$20K	(16.151)	(78.0, 81.3)	(3.232)	(18.2, 21.9)	(1.06, 1.62)	(80.0, 85.6)	
	<\$201-	1375	20.3	248	16.1	1.0	17.0	
	<\$20K	(4.123)	(18.7, 22.0)	(0.662)	(13.6, 18.8)		(14.4, 20.0)	
Education	Some college or higher	2121	50.4	485	21.0	1.24	54.8	0.04
Education	Some conege of mgner	(10.759)	(48.1, 52.8)	(2.259)	(18.5, 23.7)	(1.01, 1.54)	(50.3, 59.3)	
	High School or lower	3004	49.6	548	17.6	1.0	45.2	
	High School of lower	(10.574)	(47.2, 51.9)	(1.860)	(15.8, 19.5)		(40.7, 49.7)	
Health Insurance Coverage	Ves	4500	90.1	979	20.6	3.10	96.0	< 0.001
	103	(19.240)	(88.9, 91.2)	(3.957)	(19.0, 22.3)	(1.96, 4.89)	(93.9, 97.5)	
	No	635	9.9	55	7.7	1.0	4.0	
	110	(2.113)	(8.8, 11.1)	(0.163)	(5.1, 11.6)		(2.5, 6.1)	
Prescription	Vac	4139	93.1	912	20.9	1.28	94.3	0.16
Insurance Coverage ^f	Tes	(17.890)	(91.8, 94.2)	(3.740)	(19.2, 22.7)	(0.91, 1.81)	(92.2, 95.8)	
	No	352	6.9	68	17.1	1.0	5.7	
	110	(1.329)	(5.8, 8.2)	(0.227)	(12.8, 22.5)		(4.2, 7.8)	
Body Mass Index	$<24.99 \text{ kg/m}^2$	648	11.5	93	12.3	1.0	7.3	
	n ng/m	I	L	I	l		L	

Table 3. Prevalence of Angiotensin Receptor Blocker Use in the Prior 30 days Among US Adults with Diabetes by Social Dete	rminants of
Health and Body Mass Index ^a	

		(2.327)	(10.4, 12.8)	(0.285)	(9.8, 15.2)		(5.8, 9.2)	< 0.001
	25.00-29.99 kg/m ²	1392	26.6	256	16.7	1.45	23.1	
		(5.371)	(25.0, 28.3)	(0.896)	(13.9, 19.9)	(1.03, 2.02)	(19.6, 26.9)	
	30.00-39.99 kg/m ²	2062	45.0	451	21.6	2.00	50.6	
		(9.085)	(43.1, 46.9)	(1.967)	(19.4, 24.1)	(1.51, 2.64)	(46.5, 54.8)	
	. 40.001 / 2	689	16.5	173	21.8	2.02	18.8	
	$\geq 40.00 \text{ kg/m}^2$	(3.337)	(14.8, 18.4)	(0.729)	(17.7, 26.7)	(1.40, 2.92)	(15.4, 22.7)	

Abbreviations: OR; Odds ratio

^a Diagnosis was obtained from the health questionnaire data via participant self-report in data of 7 biannual cycles (2005-2018)

^b Values of millions and percent (95% CI) are weighted to be nationally representative

^c Indicates the odds of being on an angiotensin receptor blocker compared to the reference category

^d Indicates reference category

^eSignificance for the association of angiotensin receptor blocker use and the parameter

^fSurvey question answered by those saying "yes" to having health insurance coverage

		Obesity ^a						
		Total P	opulation		ARB Us	e (N=1528, 7.554 n	nillion)	
		N=14,296, 7	9.530 million)	P	revalence of AR	B Use	Prevalence of	ARB Use
		NY A/b		Within Subgroup			Across Subgroup	
		No.	% °	NO.	% °		% ⁵	n value
Parameter		(minions)*	(95% CI)	(minions)*	(95% CI)	(95% CI)	(95% CI)	p-value
Age	<-44	5745	43.1	124	2.2	1.0	10.1	< 0.001
Age	~-++	(34.274)	(41.7, 44.5)	(0.764)	(1.8, 2.8)		(8.2, 12.4)	
	15 61	5370	39.5	663	11.5	5.68	47.6	
	45-04	(31.388)	(38.3, 40.7)	(3.596)	(10.2, 12.9)	(4.48, 7.20)	(44.0, 51.3)	
	>-(5	3181	17.4	741	23.0	13.13	42.3	
	>=63	(13.869)	(16.4, 18.5)	(3.193)	(21.1, 25.0)	(10.32, 16.70)	(38.4, 46.2)	
a 1		6260	46.3	610	8.6	1.0	41.9	0.01
Gender	Male	(36.801)	(45.1, 47.5)	(3.162)	(7.7, 9.5)		(38.5, 45.3)	
	F 1	8036	53.7	918	10.3	1.22	58.1	
	Female	(42.729)	(52.5, 54.9)	(4.392)	(9.3, 11.3)	(1.05, 1.41)	(54.7, 61.5)	
	27 TT 1 1 1	5639	64.8	626	10.3	1.0	70.4	< 0.001
Race/	Non-Hispanic white	(51.547)	(61.8, 67.8)	(5.317)	(9.3, 11.4)		(66.3, 74.2)	
Ethnicity		3952	15.6	307	5.0	0.46	8.3	
200000	Hispanic	(12.399)	(13.6, 17.8)	(0.626)	(4.3, 5.9)	(0.38, 0.56)	(6.4, 10.6)	
		3840	14.6	503	11.2	1.10	17.2	
	Non-Hispanic black	(11.581)	(12.8, 16.6)	(1.297)	(10.1, 12.4)	(0.94, 1.28)	(14.4, 20.4)	
		865	5.0	92	7.8	0.74	4 2	
	Other race	(4.003)	(4.5. 5.7)	(0.314)	(6.3, 9.7)	(0.58, 0.93)	(3.3. 5.2)	
		10513	85.0	1088	94	0.99	85.0	0.96
Household Income	≥\$20k	(65,069)	(83 9 86 1)	(6 143)	(8 6 10 3)	(0.83, 1.19)	(82 3 87 3)	0.90
		3078	15.0	355	95	10	15.0	
	<\$20k	(11 446)	(139, 161)	(1.085)	(8 3 10 8)	1.0	(127 177)	
		7114	57.9	770	9.8	1.09	59.8	0.21
Education	Some college or higher	(45, 987)	(564593)	(4,514)	(8 9 10 8)	(0.95, 1.25)	(564 631)	0.21
		7167	42.1	756	9.1	1.0	40.2	
	High School or lower	(33.488)	(407 436)	(3,038)	(82 100)	1.0	(369 436)	
Health Insurance Coverage		1130/	83.5	1/36	10.7	3 57	0/ 3	<0.001
meanin msuranee coverage	Yes	(66 306)	(82, 2, 84, 7)	(7.110)	(0, 0, 11, 6)	(2.55, 5.01)	(023050)	<0.001
		2888	16.5	01	22	(2.33, 3.01)	57	
	No	(13 127)	(153 178)	(0.427)	(24.44)	1.0	(1 1 7 7)	
Prescription		10600	0/ 6	1257	(2.4, 4.4)	1 1 2	05 1	0.46
Insurance Coverage	Yes	(62, 265)	$(02 \ 0 \ 05 \ 1)$	(6.802)	(10.0 11.0)	$(0.82 \ 1.52)$	(025062)	0.40
insurance Coverage		(02.303)	(93.9,93.1)	(0.802)	(10.0, 11.9)	(0.62, 1.33)	(93.3, 90.3)	
	No	(2,590)	3.4 (4.0, (1)	80	9.8	1.0	4.9	
		(3.389)	(4.9, 6.1)	(0.352)	(7.4, 12.9)		(3.7, 6.3)	

Table 4. Prevalence of Angiotensin Receptor Blocker Use in the Prior 30 days Among US Adults with Obesity by Social Determinants of Health and Body Mass Index^a

Abbreviations: OR; Odds ratio

- ^a Obesity was defined as body mass index of \geq 30 kg/m² in data of 7 biannual cycles (2005-2018)
- ^b Values of millions and percent (95% CI) are weighted to be nationally representative
- ^c Indicates the odds of being on an angiotensin receptor blocker compared to the reference category
- ^d Indicates reference category
- ^eSignificance for the association of angiotensin receptor blocker use and the parameter
- ^fSurvey question answered by those saying "yes" to having health insurance coverage

Supplement

eTable 1. Prevalence of ARB Use in Prior 30 days Among Adults in the United States who Reported Being Diagnosed with Two Select Metabolic, Renal and Cardiovascular Diseases

eTable 2. Trends in Angiotensin Receptor Blocker Use in the US in the Prior 30 Days across NHANES biannual cycles 2005-2018 Among Adults with Coronary Heart Disease, Stroke, Kidney Disease and Congestive Heart Failure

eTable 3. Prevalence of Angiotensin Receptor Blocker Use in the Prior 30 days Among US Adults with Coronary Heart Disease and Stroke by Social Determinants of Health and Body Mass Index

eTable 4. Prevalence of Angiotensin Receptor Blocker Use in the Prior 30 days Among US Adults with Kidney Disease and Congestive Heart Failure by Social Determinants of Health and Body Mass Index

Diagnosis	Total Population	Total Population	ARB Use	ARB Use
_	No. ^b	0⁄0 ^b	No. ^b	% ^b
	(millions)	(95% CI)	(millions)	(95% CI)
Hypertension and Diabetes	3576	6.7	916	25.6
	(14.671)	(6.4, 7.0)	(3.751)	(23.6, 27.6)
Hypertension and Coronary	1252	2.6	304	22.8
Heart Disease	(5.754)	(2.3, 2.8)	(1.311)	(19.4, 26.5)
Hypertension and Stroke	1210	2.2	264	22.5
	(4.853)	(2.0, 2.4)	(1.089)	(19.4, 25.9)
Hypertension and Kidney	959	1.7	222	24.2
Disease	(3.728)	(1.5, 1.8)	(0.901)	(19.9, 29.0)
Hypertension and Congestive	1095	1.9	237	21.4
Heart Failure	(4.262)	(1.7, 2.1)	(0.912)	(18.2, 25.0)
Diabetes and Coronary Heart	599	1.2	151	24.1
Disease	(2.656)	(1.1, 1.4)	(0.639)	(19.0, 30.1)
Diabetes and Stroke	539	0.9	125	22.8
	(2.065)	(0.8, 1.1)	(0.470)	(18.5, 27.7)
Diabetes and Kidney Disease	524	0.9	133	25.1
	(1.889)	(0.8, 1.0)	(0.474)	(20.3, 30.6)
Diabetes and Congestive	573	1.0	130	22.9
Heart Failure	(2.199)	(0.9, 1.1)	(0.504)	(18.7, 27.7)
Coronary Heart Disease and	289	0.5	69	21.9
Stroke	(1.224)	(0.5, 0.6)	(0.268)	(16.3, 28.6)
Coronary Heart Disease and	204	0.3	56	26.2
Kidney Disease	(753)	(0.3, 0.4)	(0.197)	(19.4, 34.4)
Coronary Heart Disease and	533	0.9	111	21.2
Congestive Heart Failure	(2.118)	(0.8, 1.1)	(0.448)	(17.1, 25.9)
Stroke and Kidney Disease	192	0.3	37	19.2
	(0.758)	(0.3, 0.4)	(0.146)	(12.6, 28.3)
Stroke and Congestive Heart	290	0.5	59	20.3
Failure	(1.163)	(0.4, 0.6)	(0.236)	(14.7, 27.4)
Kidney Disease and	258	0.4	52	18.7
Congestive Heart Failure	(0.936)	(0.4, 0.5)	(0.175)	(12.8, 26.5)

eTable 1. Prevalence of ARB Use in Prior 30 days Among Adults in the United States who Reported Being Diagnosed with Two Select Metabolic, Renal and Cardiovascular Diseases^a

^a Diagnoses were obtained from the health questionnaire data via participant self-report in data of 7 biannual cycles (2005-2018)

	Coronary Heart Disease ^a	Stroke ^a	Kidney Disease ^a	Congestive Heart Failure ^a
	(N=1,644, 7.740 million)	(N=1,591, 6.583 million)	(N=1,322, 5.784 million)	(N=1,355, 5.458 million)
Biannual Cycle	ARB Use	ARB Use	ARB Use	ARB Use
	%	%	%	%
	(95% CI)	(95% CI)	(95% CI)	(95% CI)
2005-2006	12.0	15.5	12.5	15.5
	(8.6, 16.4)	(9.8, 23.7)	(8.0, 19.1)	(10.2, 22.9)
2007-2008	19.8	16.7	13.9	19.8
	(13.9, 27.4)	(12.3, 22.2)	(8.9, 21.1)	(16.0, 24.1)
2009-2010	18.0	16.6	13.9	14.3
	(13.4, 23.7)	(11.8, 22.8)	(10.1, 18.8)	(8.1, 23.8)
2011-2012	20.0	15.2	19.4	19.6
	(14.6, 26.8)	(10.1, 22.1)	(12.3, 29.2)	(12.5, 29.5)
2013-2014	18.3	18.4	14.4	17.7
	(13.7, 23.9)	(12.4, 26.3)	(7.8, 25.1)	(11.8, 25.7)
2015-2016	25.4	21.1	21.9	21.0
	(16.1, 37.7)	(14.3, 29.9)	(13.8, 32.8)	(13.5, 31.3)
2017-2018	16.1	17.1	16.8	19.4
	(9.5, 26.0)	(10.9, 25.7)	(10.1, 26.7)	(14.2, 26.0)
P for trend-value ^c	0.160	0.929	0.568	0.865

eTable 2. Trends in Angiotensin Receptor Blocker Use in the US in the Prior 30 Days across NHANES biannual cycles 2005-2018 Among Adults with Coronary Heart Disease, Stroke, Kidney Disease and Congestive Heart Failure

^a Diagnoses were obtained from the health questionnaire data via participant self-report in data of 7 biannual cycles (2005-2018)

^b Percent (95% CI) are weighted to be nationally representative

^c Significance for the association of angiotensin receptor blocker use and biannual cycles

Stroke by Social	Deter minunes of freute		Coronary Haa	urt Disaasa ^a			Strol	7 0 8	
			(N=1 644 7 740)	7 740 million)			(N=1 591 6 5	83 million)	
			ARB I	Tse			ARR	Use	
			(N=331, 1.43)	0 million)			(N=281, 1.13	3 million)	
			Prevalence	Prevalence			Prevalence	Prevalence	
			Within	Across			Within	Across	
		Participants	Subgroup	Subgroup		Participants	Subgroup	Subgroup	
		No.	% ^b	0∕0 b		No.	%b	0∕0 b	
		(millions) ^b	(96% CI)	(95% CI)	p-value ^c	(millions) ^b	(96% CI)	(95% CI)	p-value ^c
Age	<=11	7	12.2	3.2	< 0.0001	4	2.7	2.7	< 0.0001
Age	~=++	(0.045)	(5.1, 26.4)	(1.3, 7.8)		(0.014)	(1.0, 7.5)	(1.0, 7.5)	
	15-61	75	10.2	17.8		63	11.1	22.0	
		(0.254)	(7.2, 14.2)	(12.8, 24.2)		(0.249)	(7.9, 15.5)	(15.7, 29.8)	
	>=65	249	23.2	79.0		214	22.9	76.7	
	- 05	(1.131)	(19.6, 27.3)	(72.3, 84.5)		(0.870)	(19.4, 26.8)	(69.0, 83.0)	
Gender	Male	198	16.1	56.7	0.11	110	12.9	32.6	0.009
Gender	Wate	(0.811)	(13.3, 19.2)	(49.4, 63.6)		(0.369)	(9.6, 17.1)	(24.9, 41.4)	
	Female	133	23.1	43.3		171	20.6	67.4	
	1 cinaic	(0.620)	(18.2, 28.7)	(36.4, 50.6)		(0.764)	(17.2, 24.5)	(58.6, 75.1)	
Race/	Hispanic	54	14.9	5.6	0.03	39	13.9	6.2	0.36
Kace/	Inspanie	(0.080)	(11.2, 19.6)	(3.9, 8.1)		(0.070)	(9.1, 20.6)	(3.9, 9.8)	
Ethnicity	Non-Hispanic white	182	17.8	76.9		134	17.1	68.8	
		(1.100)	(14.7, 21.4)	(72.1, 81.1)		(0.780)	(13.9, 20.7)	(61.9, 75.0)	
	Non-Hispanic black	55	22.3	8.0		78	17.0	15.2	
		(0.114)	(17.5, 28.1)	(5.9, 10.7)		(0.172)	(13.9, 20.7)	(12.1, 19.0)	
	Other race	40	26.3	9.5		30	22.7	9.7	
		(0.135)	(19.0, 35.3)	(6.8, 13.0)		(0.110)	(15.3, 32.3)	(6.5, 14.3)	
Household	>\$20k	240	19.7	83.4	0.04	189	18.7	77.2	0.05
Household	<u>_</u> #20K	(1.126)	(16.6, 23.3)	(78.1, 87.7)	_	(0.845)	(15.9, 22.0)	(70.4, 82.9)	
Income	<\$20k	72	14.2	16.6		80	14.0	22.8	
		(0.224)	(10.7, 18.5)	(12.3, 21.9)		(0.249)	(10.8, 18.0)	(17.1, 29.6)	
Education	Some college or higher	156	19.6	54.5	0.33	112	16.1	40.4	0.44
Education		(0.780)	(15.9, 23.9)	(47.6, 61.3)	_	(0.458)	(12.9, 20.0)	(33.2, 48.0)	
	High School or less	175	17.3	45.5		169	18.1	59.6	
	ingn seneer er ress	(0.651)	(14.3, 20.8)	(38.7, 52.4)		(0.676)	(14.9, 21.8)	(52.0, 66.8)	
Health Insurance	Yes	321	18.8	96.5	0.39	270	17.9	95.9	0.03
Coverage		(1.381)	(16.0, 21.9)	(91.3, 98.7)	4	(1.082)	(15.3, 20.8)	(91.9, 98.0)	
	No	10	13.2	3.5		10	8.6	4.1	
		(0.049)	(5.5, 28.4)	(1.3, 8.7)		(0.045)	(4.4, 16.3)	(2.0, 8.1)	
Prescription	Yes	289	18.9	90.9	0.62	253	18.6	94.4	0.16
	105	(1.273)	(15.9, 22.2)	(85.7, 94.4)		(1.034)	(15.0, 21.6)	(90.9, 96.6)	

eTable 3. Prevalence of Angiotensin Receptor Blocker Use in the Prior 30 days Among US Adults with Coronary Heart Disease and Stroke by Social Determinants of Health and Body Mass Index

					-				
Insurance	N-	34	21.2	9.1		19	13.1	5.6	
Coverage ^d	INO	(0.127)	(13.6, 31.6)	(5.6, 14.3)		(0.061)	(7.8, 21.2)	(3.4, 9.1)	
Body Mass Index	~24 00 1 / 2	51	13.7	15.2	0.19	42	11.4	16.6	0.01
	$\leq 24.99 \text{ kg/m}^2$	(0.200)	(9.3, 19.6)	(10.3, 22.0)		(0.166)	(8.2, 15.6)	(12.1, 22.4)	
	25.00.20.001 / 2	99	17.6	32.3		71	14.8	26.9]
	25.00-29.99 kg/m ²	(0.423)	(13.0, 22.0)	(26.9, 38.1)		(0.269)	(10.7, 20.0)	(20.0, 35.2)	
	30.00-39.99 kg/m ²	128	20.8	44.7		112	21.3	44.2	
		(0.586)	(16.4, 25.9)	(38.0, 51.6)		(0.441)	(17.3, 25.9)	(36.5, 52.1)	
	≥40.00 kg/m ²	26	20.0	7.8		24	22.0	12.3]
		(0.102)	(12.2, 31.0)	(4.8, 12.3)		(0.123)	(13.3, 34.2)	(7.5, 19.5)	

^a Diagnosis was obtained from the health questionnaire data via participant self-report in data of 7 biannual cycles (2005-2018)

^b Values of millions and percent (95% CI) are weighted to be nationally representative

° Significance for the association of angiotensin receptor blocker use and the parameter

^d Survey question answered by those saying "yes" to having health insurance coverage

·		Kidney Disease ^a (N=1,322, 5.784 million)				Congestive Heart Failure ^a (N=1,355, 5.458 million)				
			ARB	Use		ARB Use				
		(N=244, 0.969 million)				(N=258, 1 million)				
			Prevalence	Prevalence			Prevalence	Prevalence		
		D (1.1.)	Within	Across		D (1) (Within	Across		
		Participants	Subgroup			Participants	Subgroup			
		(millions) ^b		(95% CD	n-value ^c	INO. (millions) ^b		(95% CD	n_value ^c	
		18	51	7.8	<0.0001	11	13.4	60	0.02	
Age	<=44	(0.075)	(2.8, 9.1)	(4.6, 12.8)	-0.0001	(0.059)	(6.9, 24.3)	(3.1, 11.1)	0.02	
		71	13.2	26.7		63	13.1	21.0		
	45-64	(0.259)	(9.5, 18.0)	(19.0, 36.2)		(0.209)	(9.1, 18.4)	(14.7, 29.0)		
		155	27.1	65.5		184	21.5	73.1		
	>=65	(0.635)	(21.8, 33.1)	(57.2, 72.9)		(0.731)	(18.2, 25.2)	(65.2, 79.8)		
0 1		118	15.4	39.8	0.38	132	16.5	47.0	0.13	
Gender	Male	(0.386)	(12.1, 19.4)	(31.7, 48.5)		(0.470)	(13.4, 20.2)	(39.6, 54.5)		
	E1-	126	17.8	60.2		126	20.3	53.0		
	Female	(0.583)	(13.7, 22.8)	(51.5, 68.3)		(0.530)	(16.7, 24.5)	(45.5, 60.4)		
Daga/	Hismonia	50	12.0	9.5	0.12	44	18.1	7.9	0.40	
Kace/	Hispanie	(0.092)	(8.4, 16.9)	(6.4, 13.8)		(0.079)	(13.1, 24.6)	(5.4, 11.6)		
Ethnicity	Non-Hispanic white	90	16.5	64.5		120	17.7	67.5		
-		(0.625)	(12.5, 21.5)	(56.1, 72.0)		(0.675)	(14.5, 21.4)	(61.6, 72.9)		
	Non-Hispanic black	78	21.3	18.9		69	18.8	16.3		
		(0.183)	(17.1, 26.2)	(13.5, 25.9)		(0.163)	(15.0, 23.3)	(12.4, 21.0)		
	Other race	26	18.0	7.1		25	24.6	8.3		
		(0.069)	(11.4, 27.3)	(4.4, 11.3)		(0.083)	(16.1, 35.7)	(5.2, 13.0)		
Household	≥\$20k	158	17.4	78.4	0.42	163	19.6	76.3	0.05	
-		(0.709)	(13.6, 22.0)	(70.3, 84.7)		(0.709)	(15.8, 24.1)	(69.8, 81.7)		
Income	<\$20k	66	15.0	21.6		73	14.3	23.7		
	• •	(0.196)	(11.1, 20.0)	(15.3, 29.7)	0.00	(0.220)	(11.4, 17.8)	(18.3, 30.2)	0.44	
Education	Some college or higher	103	16.5	49.4	0.88	99	19.4	45.9	0.44	
Luurunon		(0.479)	(11.6, 23.1)	(38.6, 60.3)		(0.459)	(15.4, 24.1)	(39.8, 52.1)		
	High School or less	141	1/.0	30.0		(0.542)	1/.0	54.1		
Uaalth		(0.490)	(13.9, 20.8)	(39.7, 61.4)	0.002	(0.342)	(14.8, 20.7)	(47.9, 60.2)	0.19	
Insurance	Yes	(0.922)	18.2	93.9 (00 0 08 2)	0.002	248 (0.058)	10.0	93./ (01.6.07.0)	0.18	
Coverage		12	57	(30.3, 30.2) A 1		10	12.0	(31.0, 37.3)		
Coverage	No	(0.040)	(26, 12, 2)	(1801)		(0.042)	$(5 \ 8 \ 23 \ 0)$	(2184)		
Prescription		216	18 5	93.4	0.86	221	18.6	89.2	0.26	
riescription	Yes	(0.870)	(151226)	(87 4 96 7)	0.00	(0.868)	(15.8, 21.8)	(835931)	0.20	
	1	(0.070)	(12.1, 22.0)	(07.1, 70.7)		(0.000)	(12.0, 21.0)	(05.5, 75.1)		

eTable 4. Prevalence of Angiotensin Receptor Blocker Use in the Prior 30 days Among US Adults with Kidney Disease and Congestive Heart Failure by Social Determinants of Health and Body Mass Index

Ingunanaa		16	176	6.6		20	24.2	10.9	
Insurance	No	10	17.0	0.0		29	24.2	10.8	
Coverage ^a	110	(0.061)	(10.0, 29.2)	(3.3, 12.6)		(0.104)	(15.7, 35.3)	(6.9, 16.5)	
Body Mass	$\leq 24.99 \text{ kg/m}^2$	36	10.6	15.2	0.03	31	13.5	13.3	0.02
Index		(0.139)	(6.6, 16.6)	(9.5, 23.4)		(0.120)	(8.6, 20.4)	(8.4, 20.3)	
	25.00.20.00 he/m ²	62	15.9	26.8		51	15.7	22.4	
3	25.00-29.99 kg/m ²	(0.245)	(11.4, 21.8)	(20.6, 34.1)		(0.202)	(11.8, 20.6)	(17.2, 28.6)	
	30.00-39.99 kg/m ²	93	21.0	44.0		119	23.2	50.9	
		(0.402)	(15.3, 28.0)	(35.0, 53.4)		(0.461)	(19.6, 27.3)	(43.1, 58.6)	
	≥40.00 kg/m ²	36	23.3	14.0]	34	15.5	13.5	
		(0.128)	(15.3, 33.8)	(8.5, 22.1)		(0.122)	(9.8, 23.7)	(9.1, 19.5)	

^a Diagnosis was obtained from the health questionnaire data via participant self-report in data of 7 biannual cycles (2005-2018)

^b Values of millions and percent (95% CI) are weighted to be nationally representative

° Significance for the association of angiotensin receptor blocker use and the parameter

^d Survey question answered by those saying "yes" to having health insurance coverage